MorphoSys to Start Share Buy-Back Program
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Start Share Buy-Back Program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
The Management Board of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX;
OTC: MPSYY) today announced the decision to repurchase own shares over the stock
market for a total purchase price of up to EUR 5.39 million (excluding ancillary
costs). The share buy-back will take place during the time period from April
9, 2015 to April 17, 2015, and is based on the authorization of the Annual
General Meeting on May 23, 2014. On the basis of the current share price (EUR
57.45; Xetra closing price as of April 7, 2015), the total purchasing volume
amounts to up to 93,820 shares or 0.36% of the registered share capital of the
Company.
The Company intends to use the shares for its long-term incentive programs for
its Executive Board and the Senior Management Group, but the shares can also be
used for all other legally permitted purposes stated in the authorization of the
Annual General Meeting of 2014.
The relevant conditions of the shareholders' resolution passed in the Annual
General Meeting 2014 on the authorization to acquire and to use its own shares
shall apply. The purchase price paid per share may not be more than 10% higher
or 20% lower than the Company's share price determined by the opening auction in
the Xetra trading system on the day of trading.
The share buy-back is to be handled independently of and uninfluenced by the
Company through an appointed bank in compliance with the safe-harbor provisions.
MorphoSys will provide regular information on the progress of the share buy-back
program on the Company's website www.morphosys.com/share-buyback.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1909558/680765.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1909558]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
10,000 cps radioactivity in 105.0m total composite mineralization; 8 New High-Grade Holes
Datum: 08.04.2015 - 17:01 Uhr
Sprache: Deutsch
News-ID 384373
Anzahl Zeichen: 4799
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Start Share Buy-Back Program"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
